AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Replimune Group Faces Securities Class Action Investigation
ByAinvest
Friday, Aug 15, 2025 10:22 am ET1min read
Faruqi & Faruqi is investigating potential claims against Replimune Group, a biotechnology company. The firm is looking into allegations of securities fraud related to the company's financial statements between November 2024 and July 2025. Investors who suffered losses during this period may contact Faruqi & Faruqi partner Josh Wilson to discuss their options. The deadline to seek lead plaintiff status is September 22, 2025.
New York, Aug. 9, 2025 — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company. The firm is looking into allegations of securities fraud related to the company's financial statements between November 2024 and July 2025. Investors who suffered losses during this period are encouraged to contact Faruqi & Faruqi partner Josh Wilson to discuss their options.The investigation is focused on allegations that Replimune and its executives made false and/or misleading statements and/or failed to disclose material issues. Specifically, the firm is examining claims that Replimune recklessly overstated the prospects of its IGNYTE trial, which resulted in the FDA deeming the trial inadequate and not well-controlled. This, in turn, led to materially false and misleading statements about Replimune's business, operations, and prospects.
On July 22, 2025, Replimune issued a press release stating that it had received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1. The CRL indicated that the FDA was unable to approve the application in its present form due to the IGNYTE trial's inadequacy. This announcement led to a significant drop in Replimune's common stock, plummeting over 73% during intraday trading.
Investors who wish to discuss their legal rights should contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The deadline to seek lead plaintiff status in a federal securities class action that has been filed against the company is September 22, 2025.
References:
[1] https://www.morningstar.com/news/globe-newswire/9510411/shareholder-action-reminder-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-replimune
[2] https://www.prnewswire.com/news-releases/levi--korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-september-22-2025-in-replimune-group-inc-lawsuit--repl-302530663.html
[3] https://www.morningstar.com/news/pr-newswire/20250809ny47607/faruqi-faruqi-reminds-replimune-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-22-2025-repl
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet